INS and cancer: Our study had enough statistical power for the assessment of both sex- and site-specific cancer outcomes by cumulative durations; this assessment is considered by Renehan [16] to be an essential feature of an appropriately conducted pharmaco-epidemiological study on the link between insulin analogues and cancer risk.